BiotechTube
Home/HCW Biologics/Rebecca Byam
RB

Rebecca Byam

Chief Financial Officer

HCW Biologics

Therapeutic Areas

Autoimmune DiseasesOncologySenescence-associated Dysplasia

HCW Biologics Pipeline

DrugIndicationPhase
HCW9206Reagent for CAR-T/NK Cell Manufacturing (Cancer, Infectious Diseases)Commercial-Ready
HCW9201Reagent for Immunotherapeutic ProductionCommercial-Ready
HCW11-006Not Specified (In Vivo Applications)Not Disclosed
TOBI-based moleculeSolid Tumors (Ovarian, Pancreatic Cancer)Phase 1/2
Fusion ImmunotherapeuticAutoimmune DiseaseClinical Trial

Leadership Team at HCW Biologics

HC
Hing C. Wong
Founder, Chief Executive Officer
PR
Peter Rhode
Chief Scientific Officer and Vice President Clinical Operations
LF
Lee Flowers
Senior Vice President Business Development
JE
Jack Egan
Vice President of Manufacturing and Development
NV
Nicole Valdivieso
Vice President Legal Affairs
ST
Scott T. Garrett
Board of Directors
RS
Rick S. Greene
Board of Directors
LM
Lisa M. Giles
Board of Directors
View full HCW Biologics profile